STAAR Surgical appoints Deborah Andrews permanent CFO, forms Capital Stewardship Committee, IR head leaves

STAAR SURGICAL CO

Deborah Andrews appointed CFO effective June 25, 2025; she served as interim CFO since March 2025 and previously held the role from 2007-2013 and 2017-2020.
Compensation: base salary $495k, target bonus 55%, equity award valued at $1.4M (50% RSUs vesting over 3 years, 50% PSUs tied to revenue targets through 2027).
Company on track to achieve $225M annual SG&A run rate ahead of schedule.
Board forms new Capital Stewardship Committee chaired by Lilian Y. Zhou to guide capital allocation and oversight.
Brian Moore, VP Investor Relations and Corporate Development, will depart effective June 27, 2025.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Deborah Andrews

Chief Financial Officer

STAA · STAAR SURGICAL CO

Effective: 2025-06-25
Filed: June 25, 2025, 7:59 PM ET

On June 25, 2025, STAAR Surgical Company (the “Company”) announced that its Board of Directors (the “Board”) appointed Deborah Andrews as Chief Financial Officer of the Company, effective June 25, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Deborah Andrews was appointed as Chief Financial Officer at STAAR SURGICAL CO.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 25, 2025, STAAR Surgical Company (the “Company”) announced that its Board of Directors (the “Board”) appointed Deborah Andrews as Chief Financial Officer of the Company, effective June 25, 2025 (the “Effective Date”).

View on SEC.gov

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0000950170-25-089733

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.